Trial intelligence / Profile preview

Phase II study of QLS31905 + QL2107 + XELOX as first-line treatment for CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

CTR20251539Phase 2Active

Sponsor

Qilu Pharmaceutical

Start

Jun 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1